Index NDX, S&P 500
P/E 27.21
EPS (ttm) 8.01
Insider Own 0.76%
Shs Outstand 144.90M
Perf Week -5.53%
Market Cap 31.71B
Forward P/E 12.48
EPS next Y 17.45
Insider Trans -0.11%
Shs Float 144.50M
Perf Month 7.58%
Income 1.17B
PEG 8.50
EPS next Q 3.98
Inst Own 90.04%
Short Float 2.18%
Perf Quarter -2.64%
Sales 9.29B
P/S 3.42
EPS this Y 6.14%
Inst Trans 0.82%
Short Ratio 2.56
Perf Half Y -5.81%
Book/sh 104.48
P/B 2.08
EPS next Y 11.72%
ROA 4.56%
Short Interest 3.15M
Perf Year -28.15%
Cash/sh 7.38
P/C 29.52
EPS next 5Y 3.20%
ROE 8.04%
52W Range 189.44 - 319.76
Perf YTD -15.83%
Dividend Est. -
P/FCF -
EPS past 5Y -18.05%
ROI 5.32%
52W High -31.88%
Beta -0.03
Dividend TTM -
Quick Ratio 1.32
Sales past 5Y -4.53%
Gross Margin 68.31%
52W Low 14.98%
ATR (14) 5.45
Dividend Ex-Date -
Current Ratio 2.10
EPS Y/Y TTM -62.75%
Oper. Margin 18.67%
RSI (14) 47.91
Volatility 2.24% 2.54%
Employees 7570
Debt/Eq 0.46
Sales Y/Y TTM -2.49%
Profit Margin 12.56%
Recom 1.64
Target Price 284.14
Option/Short Yes / Yes
LT Debt/Eq 0.44
EPS Q/Q 0.93%
Payout 0.00%
Rel Volume 0.63
Prev Close 218.06
Sales Surprise -0.80%
EPS Surprise 5.78%
Sales Q/Q -5.62%
Earnings Apr 24 BMO
Avg Volume 1.23M
Price 217.81
SMA20 -1.92%
SMA50 2.26%
SMA200 -8.72%
Trades
Volume 770,843
Change -0.11%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-14-24 Reiterated
Needham
Buy
$305 → $300
Feb-14-24 Downgrade
Wells Fargo
Overweight → Equal Weight
$315 → $240
Jan-24-24 Downgrade
UBS
Buy → Neutral
$311 → $276
Dec-20-23 Resumed
Cantor Fitzgerald
Overweight
$311
Dec-07-23 Upgrade
Raymond James
Mkt Perform → Outperform
$283
Sep-06-23 Initiated
HSBC Securities
Buy
$360
Jul-27-23 Initiated
Scotiabank
Sector Outperform
$327
Jul-24-23 Reiterated
UBS
Buy
$346 → $335
May-01-23 Upgrade
Guggenheim
Neutral → Buy
$270 → $350
Apr-17-23 Upgrade
Piper Sandler
Neutral → Overweight
$280 → $346
Oct-26-22 Upgrade
Goldman
Neutral → Buy
$220 → $370
Oct-13-22 Upgrade
Stifel
Hold → Buy
$223 → $299
Oct-07-22 Upgrade
Argus
Hold → Buy
$300
Sep-28-22 Upgrade
Robert W. Baird
Neutral → Outperform
$224 → $340
Sep-28-22 Upgrade
Mizuho
Neutral → Buy
$207 → $270
Sep-28-22 Upgrade
BMO Capital Markets
Market Perform → Outperform
$217 → $360
Apr-18-22 Upgrade
Wells Fargo
Equal Weight → Overweight
$235 → $265
Mar-08-22 Downgrade
Stifel
Buy → Hold
$304 → $223
Mar-03-22 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$227 → $248
Feb-04-22 Reiterated
Wolfe Research
Peer Perform
$244 → $217
Show Previous Ratings
May-24-24 11:31AM
May-23-24 10:06AM
08:54AM
(Pharmaceutical Technology)
May-22-24 07:28PM
09:55AM
08:25AM
Loading…
08:25AM
07:37AM
07:30AM
07:19AM
May-21-24 09:50AM
May-17-24 06:15AM
May-16-24 01:37PM
12:46PM
09:29AM
08:50AM
08:05AM
Loading…
08:05AM
07:51AM
07:37AM
07:30AM
07:30AM
May-15-24 04:05PM
(Investor's Business Daily)
01:29PM
12:12PM
11:02AM
(Investor's Business Daily)
08:25AM
04:26AM
12:17AM
May-14-24 07:33PM
07:30PM
May-13-24 07:57PM
08:00AM
Loading…
May-11-24 08:00AM
May-10-24 10:11AM
May-09-24 06:30AM
May-08-24 03:15PM
02:01PM
07:01AM
(Thomson Reuters StreetEvents)
May-04-24 10:27AM
May-03-24 12:01PM
May-02-24 07:30AM
Apr-30-24 11:15AM
(Investor's Business Daily)
Apr-29-24 10:03AM
09:50AM
Apr-26-24 11:27AM
05:00AM
01:02AM
Apr-25-24 04:05PM
02:15PM
07:00AM
(The Wall Street Journal)
01:23AM
(Thomson Reuters StreetEvents)
Apr-24-24 06:18PM
04:19PM
(Investor's Business Daily)
04:01PM
02:12PM
12:57PM
12:45PM
12:28PM
11:53AM
11:13AM
11:08AM
10:39AM
10:28AM
10:05AM
09:39AM
(The Wall Street Journal)
09:34AM
09:30AM
09:00AM
08:39AM
(The Wall Street Journal)
08:32AM
07:45AM
07:15AM
06:48AM
06:45AM
(Investor's Business Daily)
06:45AM
Apr-23-24 12:23AM
Apr-19-24 09:39AM
09:15AM
Apr-17-24 10:01AM
Apr-12-24 10:00AM
Apr-10-24 06:09PM
Apr-01-24 05:50PM
04:02PM
Mar-31-24 07:30PM
11:53AM
Mar-28-24 08:00AM
(Investor's Business Daily)
Mar-27-24 12:18PM
Mar-26-24 11:21AM
Mar-25-24 05:50PM
Mar-22-24 07:05AM
06:57AM
Mar-21-24 05:14PM
09:17AM
04:39AM
Mar-18-24 05:50PM
10:16AM
Mar-15-24 09:34AM
Mar-14-24 11:30AM
Mar-12-24 05:50PM
Mar-11-24 12:44PM
09:00AM
Mar-08-24 04:11PM
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Keeney Adam Head of Corporate Development May 01 '24 Option Exercise 0.00 938 0 938 May 03 08:00 PM Singhal Priya Head of Development Apr 02 '24 Sale 213.09 93 19,817 4,886 Apr 03 08:24 PM Murphy Nicole Head of Pharm Ops and Tech Apr 01 '24 Option Exercise 0.00 240 0 9,751 Apr 03 08:11 PM Singhal Priya Head of Development Feb 22 '24 Sale 221.23 262 57,962 4,886 Feb 26 07:54 PM Singhal Priya Head of Development Feb 16 '24 Option Exercise 0.00 1,208 0 5,429 Feb 21 09:27 PM ALEXANDER SUSAN H EVP Chief Legal Officer Feb 16 '24 Option Exercise 0.00 5,037 0 52,506 Feb 21 09:39 PM Gregory Ginger EVP, Human Resources Feb 16 '24 Option Exercise 0.00 4,704 0 14,341 Feb 21 09:36 PM Izzar Rachid Head of Global Product Strat. Feb 16 '24 Option Exercise 0.00 2,017 0 10,014 Feb 21 09:33 PM Kramer Robin Chief Accounting Officer Feb 16 '24 Option Exercise 0.00 1,345 0 6,354 Feb 21 09:31 PM MCDONNELL MICHAEL R EVP, Chief Financial Officer Feb 16 '24 Option Exercise 0.00 6,720 0 20,692 Feb 21 09:29 PM Murphy Nicole Head of Pharm Ops and Tech Feb 16 '24 Option Exercise 0.00 1,260 0 9,624 Feb 21 09:28 PM Singhal Priya Head of Development Feb 16 '24 Sale 221.49 108 23,921 5,148 Feb 21 09:27 PM Rowinsky Eric K Director Feb 15 '24 Buy 222.54 455 101,256 20,629 Feb 20 09:13 PM Singhal Priya Head of Development Feb 12 '24 Sale 239.45 419 100,330 4,516 Feb 13 06:06 PM Singhal Priya Head of Development Feb 09 '24 Option Exercise 0.00 1,212 0 5,309 Feb 13 06:06 PM Murphy Nicole Head of Pharm Ops and Tech Feb 09 '24 Option Exercise 0.00 2,272 0 9,529 Feb 13 06:04 PM MCDONNELL MICHAEL R EVP, Chief Financial Officer Feb 09 '24 Option Exercise 0.00 3,257 0 17,555 Feb 13 06:03 PM Kramer Robin Chief Accounting Officer Feb 09 '24 Option Exercise 0.00 833 0 5,523 Feb 13 06:01 PM Gregory Ginger EVP, Human Resources Feb 09 '24 Option Exercise 0.00 2,158 0 11,778 Feb 13 06:14 PM ALEXANDER SUSAN H EVP Chief Legal Officer Feb 09 '24 Option Exercise 0.00 2,575 0 50,021 Feb 13 05:56 PM Izzar Rachid Head of Global Product Strat. Feb 09 '24 Option Exercise 0.00 1,515 0 9,081 Feb 13 06:00 PM MCDONNELL MICHAEL R EVP, Chief Financial Officer Feb 08 '24 Option Exercise 0.00 2,335 0 15,063 Feb 09 08:03 PM Murphy Nicole Head of Pharm Ops and Tech Feb 08 '24 Option Exercise 0.00 2,101 0 7,895 Feb 09 08:01 PM Kramer Robin Chief Accounting Officer Feb 08 '24 Option Exercise 0.00 788 0 4,943 Feb 09 08:06 PM Gregory Ginger EVP, Human Resources Feb 08 '24 Option Exercise 0.00 1,635 0 10,118 Feb 09 08:14 PM Izzar Rachid Head of Global Product Strat. Feb 08 '24 Option Exercise 0.00 2,043 0 8,187 Feb 09 08:11 PM ALEXANDER SUSAN H EVP Chief Legal Officer Feb 08 '24 Option Exercise 0.00 2,190 0 48,101 Feb 09 08:16 PM Singhal Priya Head of Development Feb 02 '24 Sale 245.93 634 155,920 4,097 Feb 05 06:38 PM Singhal Priya Head of Development Feb 01 '24 Option Exercise 0.00 1,828 0 5,292 Feb 05 06:38 PM Singhal Priya Head of Development Dec 11 '23 Sale 248.00 110 27,280 3,464 Dec 12 05:06 PM Kramer Robin Chief Accounting Officer Dec 08 '23 Option Exercise 0.00 351 0 4,325 Dec 12 05:02 PM Singhal Priya Head of Development Dec 08 '23 Option Exercise 0.00 426 0 3,780 Dec 12 05:06 PM BIOGEN INC. 10% Owner Sep 26 '23 Sale 0.50 6,000,000 3,000,000 17,652,466 Sep 28 05:30 PM Singhal Priya Head of Development Sep 05 '23 Sale 269.43 431 116,124 3,354 Sep 06 06:06 PM MCDONNELL MICHAEL R EVP, Chief Financial Officer Sep 01 '23 Option Exercise 0.00 5,285 0 14,060 Sep 06 06:08 PM Singhal Priya Head of Development Sep 01 '23 Option Exercise 0.00 1,668 0 4,592 Sep 06 06:06 PM Singhal Priya Head of Development Jul 03 '23 Sale 282.87 81 22,912 2,924 Jul 05 05:33 PM Singhal Priya Head of Development Jun 30 '23 Option Exercise 0.00 315 0 3,158 Jul 05 05:33 PM Izzar Rachid Head of Global Product Strat. Jun 30 '23 Option Exercise 0.00 504 0 6,388 Jul 05 05:37 PM Kramer Robin Chief Accounting Officer Jun 30 '23 Option Exercise 0.00 252 0 4,096 Jul 05 05:35 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite